scholarly article | Q13442814 |
P356 | DOI | 10.1007/S00018-003-3305-3 |
P8608 | Fatcat ID | release_5gxlbbjfjvcxnfczyal6csrdha |
P698 | PubMed publication ID | 14685691 |
P50 | author | Guo-jun Chen | Q43183546 |
P2093 | author name string | S M de la Monte | |
J R Wands | |||
E Rivera | |||
P2860 | cites work | A randomized trial of rosuvastatin in the prevention of venous thromboembolism | Q37262627 |
The JUPITER trial: results, controversies, and implications for prevention | Q38469911 | ||
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial | Q38473723 | ||
Is hsCRP Back on Board? Implications from the JUPITER Trial | Q38474718 | ||
Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. | Q40442526 | ||
C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany | Q40524614 | ||
C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study | Q40828366 | ||
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events | Q43656468 | ||
Concentrations of low-density lipoprotein cholesterol and total cholesterol among children and adolescents in the United States | Q44298314 | ||
The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina | Q58230388 | ||
Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease | Q24649709 | ||
Use of multiple biomarkers to improve the prediction of death from cardiovascular causes | Q28280099 | ||
Inflammation in atherosclerosis | Q29547428 | ||
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein | Q29547752 | ||
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association | Q30434464 | ||
Genetic variation in Fc gamma receptor IIa and risk of coronary heart disease: negative results from two large independent populations | Q33456200 | ||
From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey | Q33520621 | ||
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease | Q34311841 | ||
National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease | Q34602361 | ||
Genetically elevated C-reactive protein and ischemic vascular disease | Q34868720 | ||
The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines | Q34907937 | ||
Novel and conventional biomarkers for prediction of incident cardiovascular events in the community | Q34960396 | ||
C-reactive protein: risk marker or mediator in atherothrombosis? | Q35775733 | ||
Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein | Q36027468 | ||
Biomarkers of atherosclerotic plaque instability and rupture | Q36643429 | ||
The use of high-sensitivity assays for C-reactive protein in clinical practice | Q37090943 | ||
P433 | issue | 12 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 2679-2691 | |
P577 | publication date | 2003-12-01 | |
P1433 | published in | Cellular and Molecular Life Sciences | Q5058352 |
P1476 | title | Neuronal thread protein regulation and interaction with microtubule-associated proteins in SH-Sy5y neuronal cells | |
P478 | volume | 60 |
Q95277354 | Aerobic Glycolysis in the Retina: Functional Roles of Pyruvate Kinase Isoforms |
Q34020000 | Alzheimer's disease is type 3 diabetes-evidence reviewed |
Q28259585 | Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease |
Q35997881 | Brain metabolic dysfunction at the core of Alzheimer's disease |
Q35997824 | Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease |
Q38561865 | Linking insulin with Alzheimer's disease: emergence as type III diabetes |
Q47113718 | Mechanisms linking brain insulin resistance to Alzheimer's disease |
Q58805850 | Metabolic Syndrome Exacerbates the Recognition Memory Impairment and Oxidative-Inflammatory Response in Rats with an Intrahippocampal Injection of Amyloid Beta 1-42 |
Q39195275 | Metabolism-Centric Overview of the Pathogenesis of Alzheimer's Disease |
Q58795095 | Pin1 Modulation in Physiological Status and Neurodegeneration. Any Contribution to the Pathogenesis of Type 3 Diabetes? |
Q37035260 | Practical utility of urinary assay in the diagnosis of Alzheimer's disease: AlzheimAlert |
Q35040395 | Role of central nervous system insulin resistance in fetal alcohol spectrum disorders |
Q58788781 | The association between urinary Alzheimer-associated neuronal thread protein and cognitive impairment in late-life depression: a controlled pilot study |
Q57791805 | Type 2 Diabetes Mellitus and Alzheimer's Disease: Role of Insulin Signalling and Therapeutic Implications |
Q34432135 | Type 3 diabetes is sporadic Alzheimer׳s disease: mini-review |
Q42363345 | Urine AD7c-NTP Predicts Amyloid Deposition and Symptom of Agitation in Patients with Alzheimer's Disease and Mild Cognitive Impairment |
Search more.